Join the club for FREE to access the whole archive and other member benefits.

UNITY Biotechnology expands trial of osteoarthritis senolytic

22-Jan-2019

Key points from article :

UBX0101 currently in phase 1 trial for osteoarthritis (OA) of the knee.

UNITY Biotechnology encouraged by the safety and tolerability results so far.

Enrolling an additional 24 patients at the highest evaluated dose (4mg).

Part B of trial will provide an increased sample size for SASP assessment .

Will enable further evaluation the impact of UBX0101 on SASP.

Human clinical trial is the first study of a senolytic drug in patients with OA.

Initial results must be promising to enrol more patients at highest dosage

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Chief Medical Officer at Unity Biotechnology.

Company

Biotechnology company devoted to research of restoring human health